 |
| The race is on to find a treatment for Nonalcoholic Steatohepatitis (NASH), a silent liver epidemic that's asymptomatic and hard to diagnose. A next-generation approach to NASH clinical trials uses anonymized EHR and claims data, non-invasive diagnostics, and innovative site models. This can help you speed recruitment, optimize sites, shorten timelines and cut development costs.
|
|
| Attend this live webinar and learn how QuintilesIMS can help you achieve your goals in developing your NASH treatment.
|
|
| What will you gain?
|
 |
| We will provide a comprehensive overview of NASH, and the complexity that makes this disease hard to diagnose. You can execute your NASH trials knowing you have:
|
|
• |
|
Use of curated data to optimize protocols and target sites |
|
|
• |
|
Novel technology to screen and stratify patients |
|
|
• |
|
An innovative site support model to better identify patients and accelerate recruitment |
|
|
|
|
|
|
|
| Presenters: |
|
Mark H. Delegge, MD
Senior Medical Director, QuintilesIMS |
|
Gavin Nichols
VP CRO/Life Science, Perspectum Diagnostics |
|
| Moderator: |
|
Lisa Henderson
Editorial Director, Applied Clinical Trials |
|
|
|
|
|
For technical questions about this webinar,
please contact Kristen Moore at kristen.moore@ubm.com |
|
|
|
| |
|
Contact us at
www.quintilesims.com
|
|
|
|
